This review discusses recent advances in the understanding of the biology of neuroblastoma, particular attention is paid to the emerging molecular and cytogenetic factors used to determine the strategy of treatment and prognosis in patients with this tumour. In addition, the genetic model of neuroblastoma development and its application in the process of stratification of patients into risk groups is presented.